Free Biopharma Daily Stock Updates - 04/29/21

$XBI $138.06 -1.17%

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

Covid Updates

$VRNA -5.56% Last week ensifentrine reported was well tolerated in patients hospitalized with COVID-19. source




Pipeline Updates

$ELOX -0.92% Adding new study arm to ongoing Phase 2 trial of ELX-02 to treat CF. source


$IDRA -5.6% Continuing to explore potential for tilsotolimod after disappointing ORR results in advanced melanoma. source


$XERS -4.0% MHRA approved Ogluo injection to treat sever hypoglycaemia. source


$PHAT -0.2% Pivotal Phase 3 trial of vonoprazan met primary and secondary endpoints. source


$PLX -9.9% Inspection of facility required (reported on 4/28) before BLA approval. source


$TRIL +6.5% Doses first patient in Phase 1b study on 4/28. source


$GRTX +22.8% Interim data analysis of Phase 1/2 trial reported; expect final results during second half of year. source


$SELB -19.0% Submission of IND for MMA-101 to be delayed due to manufacturing issue. source


$ADVM -62.3% Suspected Unexpected Serious Adverse Reaction of hypotony reported in INFINITY trial. source


$GALT -16.9% Presented at NASH congress today and reviewed scientific and clinical activities in NASH cirrhosis. source


$MORF -2.5% Received acceptance to present full MORF-057 Phase 1 data set at the ECCO’21 Virtual Congress in July. source


$MGNX +1.0% Will present MGC018 data at ASCO in June 2021. source


$EVLO +1.2% Presented EDP1815 positive Phase 1b data at Atopic Dermatitis meeting. source


$BPMC 1.7% Preparing to launch avapritinib in advanced SM this quarter. source


$AMRN +1.0% VAZKEPA in Europe to be launched in third quarter of 2021. source


$AGIO +0.7% Phase 3 study data to be presented at EHA 2021. source


$ARDX -6.1% PDUFA date for Tenapanor extended by three months to July 29, 2021. source


$APLS +6.5% Application for pegcetacoplan under review with PDUFA date of 5/14/2021; Phase 3 data from PNH trial expected in second quarter 2021. source


$IBRX -7.2% Launched Phase 2 trial of Anktiva to treat acute HIV infection. source


$JAGX -8.4% Poster presentation accepted for ASCO 2021 to present data on Mytesi. source


$ANVS -2.5% Plan to study ANVS401 to normalize brain development in down syndrome. source


$CARA -45.4% Phase 2 KARE trial of KORSUVA reports topline results. source


$LTRN -0.6% RADR AI platform is improving drug discovery and development; exceeded 4.6 billion datapoints. source


$LABP -2.6% First patient dosed in NX-13 Phase 1b trial. source


$APTX -6.0% Phase 2 positive data for NYX-783 reported at Society of Biological Psychiatry Annual meeting. source


$AERI -1.5% Enrollment in AR-15512 COMET-1 Phase 2b trial completed. source




Finance Updates

$INRLF +13.1% Launhces proposed global offering. source


$OCUL +22.7% Presenting financials on 5/6; presenting clinical programs at ARVO on 5/2. source


$ALDX -10.2% Announced pricing of 10M shares of common stock on 4/28. Will report financials on 5/6. source


$MIRM -4.7% Entered into exclusive licensing agreement with CANbridge Pharmaceuticals. source


$CAPR +14.9% Signed licensing agreement with Johns Hopkins University to expand exosome platform technology. source


$XLRN -1.2% Expect to report $112M in net sales of REBLOZYL in first quarter of 2021. source


0 comments